Provention Bios Phase 2a Trial of its Oral CSF1R Inhibitor Fails to Meet Primary Endpoint in Patients with Moderate to Severe Crohns Disease

OLDWICK N.J. Oct. 22 2019 PRNewswire &8212; Provention Bio Inc. Nasdaq PRVB a clinical stage biopharmaceutical company dedicated to intercepting and preventing immunemediated disease today announced topline results from its randomized placebocontrolled...